Measurement of α-synuclein as protein cargo in plasma extracellular vesicles.
Parkinson’s Disease
alpha synuclein
biomarker
exosomes
extracellular vesicles
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
05 Nov 2024
05 Nov 2024
Historique:
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
ppublish
Résumé
Extracellular vesicles (EVs) are released by all cells and hold great promise as a class of biomarkers. This promise has led to increased interest in measuring EV proteins from both total EVs as well as brain-derived EVs in plasma. However, measuring cargo proteins in EVs has been challenging because EVs are present at low levels, and EV isolation methods are imperfect at separating EVs from free proteins. Thus, knowing whether a protein measured after EV isolation is truly inside EVs is difficult. In this study, we developed methods to measure whether a protein is inside EVs and quantify the ratio of a protein in EVs relative to total plasma. To achieve this, we combined a high-yield size-exclusion chromatography protocol with an optimized protease protection assay and Single Molecule Array (Simoa) digital enzyme-linked immunoassays (ELISAs) for ultrasensitive measurement of proteins inside EVs. We applied these methods to analyze α-synuclein and confirmed that a small fraction of the total plasma α-synuclein is inside EVs. Additionally, we developed a highly sensitive Simoa assay for phosphorylated α-synuclein (phosphorylated at the Ser129 residue). We found enrichment in the phosphorylated α-synuclein to total α-synuclein ratio inside EVs relative to outside EVs. Finally, we applied the methods we developed to measure total and phosphorylated α-synuclein inside EVs from Parkinson's disease and Lewy body dementia patient samples. This work provides a framework for determining the levels of proteins in EVs and represents an important step in the development of EV diagnostics for diseases of the brain, as well as other organs.
Identifiants
pubmed: 39475636
doi: 10.1073/pnas.2408949121
doi:
Substances chimiques
alpha-Synuclein
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2408949121Subventions
Organisme : Michael J. Fox Foundation for Parkinson's Research (MJFF)
ID : 2021A017224
Organisme : Chan Zuckerberg Initiative (CZI)
ID : NDCN
Déclaration de conflit d'intérêts
Competing interests statement:D.R.W. is a founder, member of the Board of Directors, and equity holder in Quanterix. His interests were reviewed and are managed by BWH and Partners HealthCare in accordance with their conflict of interest policies. G.M.C. Disclosures: https://arep.med.harvard.edu/gmc/tech.html. The authors have filed IP on methods for EV isolation and analysis.